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SHORT COMMUNICATION 
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ABSTRACT 
Background: It is often assumed that individuals with posttraumatic stress disorder (PTSD) 
who overreport their symptoms should be excluded from trauma-focused treatments. 
Objective: To investigate the effects of a brief, intensive trauma-focused treatment pro-
gramme for individuals with PTSD who are overreporting symptoms. 
Methods: Individuals (n = 205) with PTSD participated in an intensive trauma-focused 
treatment programme consisting of EMDR and prolonged exposure (PE) therapy, physical 
activity and psycho-education. Assessments took place at pre- and post-treatment 
(Structured Inventory of Malingered Symptomatology; SIMS, Clinician Administered PTSD 
Scale for DSM-5; CAPS-5). 
Results: Using a high SIMS cut-off of 24 or above, 14.1% (n = 29) had elevated SIMS scores 
(i.e. ‘overreporters’). The group of overreporters showed significant decreases in PTSD- 
symptoms, and these treatment results did not differ significantly from other patients. 
Although some patients (35.5%) remained overreporters at post-treatment, SIMS scores 
decreased significantly during treatment. 
Conclusion: The results suggest that an intensive trauma-focused treatment not only is 
a feasible and safe treatment for PTSD in general, but also for individuals who overreport 
their symptoms. 
Los efectos del sobre-informe de síntomas en los resultados del tra-
tamiento para TEPT  
Antecedentes: Generalmente se asume que individuos con trastorno de Estrés 
Postraumático (TEPT) que sobre-informan sus síntomas debiesen ser excluidos de tratamien-
tos centrados en el trauma. 
Objetivo: Investigar los efectos de un programa de tratamiento centrado en el trauma breve 
e intensivo en individuos con TEPT que sobre-informan síntomas. 
Métodos: Individuos (n=205) con TEPT participaron en un programa de tratamiento inten-
sivo centrado en el trauma, consistente en EMDR y terapia de exposición prolongada (PE por 
sus siglas en inglés), actividad física y Psicoeducación. Se realizaron evaluaciones pre y post 
tratamiento (Inventario Estructurado de Sintomatología Simulada SIMS, Escala de TEPT para 
el DSM-5 administrada por el Clínico CAPS-5) 
Resultados: Usando un corte en el inventario SIMS de 24 o mayor, 14.1% (n=29) tenía 
elevados puntajes SIMS (es decir, los ‘sobre-informadores’). El grupo de sobre-informadores 
mostró un descenso significativo en los síntomas de TEPT, y estos resultados de tratamiento 
no fueron significativamente diferentes al del resto de los pacientes. Aunque algunos 
pacientes (35.5%) se mantuvieron sobre-informadores posterior al tratamiento, los puntajes 
SIMS disminuyeron significativamente durante el tratamiento. 
Conclusión: Los resultados sugieren que un tratamiento intensivo centrado en el trauma no 
es solo factible y seguro para el TEPT en general, sino que también para individuos que 
sobre-informan sus síntomas. 
症状的过度报告对PTSD治疗结果的影响  
背景: 通常认为, 过度报告症状的创伤后应激障碍 (PTSD) 患者, 应被排除于聚焦创伤治疗之 
外。 
目的: 探究一个简短的聚焦创伤强化治疗方案对过度报告症状的PTSD患者的效果。 
方法: 225名PTSD患者参加了一项聚焦创伤的强化治疗方案, 包括EMDR和延长暴露 (PE) 疗 
法, 体育锻炼和心理教育。在治疗前, 后进行评估 (诈病症状结构量表: SIMS, 临床用DSM-5 
PTSD量表: CAPS-5) 。 
结果: 使用24或以上的高SIMS临界值, 有14.1％ (n = 29) 的SIMS得分升高 (即‘过度报告者’) 
。过度报告者组表现为PTSD症状的明显减少, 并且这些治疗结果与其他患者无显著差异。 
虽然一些患者 (35.5％) 在治疗后仍是过度报告者, 但治疗期间SIMS得分显著下降。 
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HIGHLIGHTS 
• Overreporting symptoms 
are often seen as an contra- 
indication for treatment. 
• PTSD-patients who 
overreported symptoms 
benefitted from trauma- 
focused treatment. 
• Overreporting symptoms 
may have other underlying 
reasons than malingering. 
• Overreporting patients 
should not be excluded 
from trauma-focused 
treatment. 
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结论: 结果表明, 聚焦创伤的强化治疗不仅是一种对于一般PTSD可行且安全的治疗方法, 对 
于过度报告症状的个体也是如此。   
1. Introduction 
Symptom overreporting has been associated with 
posttraumatic stress disorder (PTSD) in several stu-
dies, and has often been interpreted as ‘malingering’ 
(e.g. Hall & Hall, 2006). The prevalence of malinger-
ing among PTSD-patients (in the context of 
a forensic assessment) is estimated at 15% ± 15% 
(e.g. Young, 2015). However, some researchers have 
emphasized that symptom overreporting may have 
other underlying reasons than malingering per se 
(Merckelbach, Dandachi-FitzGerald, van Helvoort, 
Jelicic, & Otgaar, 2019), such as inattentive respond-
ing that may be caused by specific genuine PTSD- 
symptoms. For instance, difficulties with concentra-
tion, one of the key symptoms of PTSD, may lead to 
low attention, and thereby to inadequate answering of 
items on a questionnaire. Also, dissociative symptoms 
and alexithymia, symptoms often seen in PTSD- 
patients, have been found to be related with symptom 
overreporting (Brady, Bujarski, Feldner, & Pyne, 
2017; Merckelbach, Prins, Boskovic, Niesten, & 
Campo, 2018). Personality traits, such as fantasy pro-
neness have also been found to contribute to over-
reporting (Peace & Masliuk, 2011). The issue of the 
underlying cause of symptom overreporting is clini-
cally relevant, because it may have an impact on 
treatment decision making. For example, if PTSD 
patients are caught overreporting their symptoms, 
this is not seldom interpreted as malingering. 
Consequently, it is often recommended to exclude 
these patients from trauma treatment because treat-
ment would probably be less effective and therefore 
not useful (e.g. Crawford et al., 2017). However, when 
overreporting is related to genuine PTSD-related 
symptoms, treatment may still be indicated and 
effective. 
Thus far, however, little is known about the effec-
tiveness of trauma-focused treatment regarding 
patients who overreport symptoms in clinical set-
tings. In one study using veterans with PTSD (Hale, 
Rodriguez, Wright, Driesenga, & Spates, 2019), it was 
found that symptom overreporting, as measured with 
the Minnesota Multiphasic Personality Inventory 
(MMPI), was related to the severity of baseline 
pathology, but not to trauma-focused treatment out-
come. To enhance our understanding concerning the 
influence of symptom overreporting on treatment 
outcome in clinical settings, in the present study, we 
assessed symptom overreporting with the commonly 
used Structured Inventory of Malingered 
Symptomatology (SIMS; Smith & Burger, 1997). In 
a sample of patients who underwent a brief intensive 
trauma-focused treatment programme for PTSD, we 
tested whether patients who overreported symptoms 
would show significantly less decrease in PTSD- 
symptoms associated with trauma-focused treatment 
compared to those who did not overreport. In addi-
tion, we explored the effects of treatment on the 
SIMS-scores. 
2. Method 
2.1. Participants 
The study participants were 264 PTSD patients who 
were treated between August 2017 and January 2018 
at the PSYTREC clinic. Inclusion criteria were: (1) 
being at least 18 years old, (2) having a diagnosis of 
PTSD established with the Clinician Administered 
PTSD Scale-5 (CAPS-5) for Diagnostic and 
Statistical Manual of Mental Disorders, 5th Edition 
(DSM-5; APA, 2013), (3) having sufficient knowledge 
of the Dutch language and (4) no suicide attempts in 
the past three months. For 28 participants a complete 
baseline assessment (CAPS-5 and SIMS) was missing, 
for 3 patients the CAPS-5 post-treatment was miss-
ing, 2 patients dropped out prematurely, and 26 par-
ticipants did not give their consent. This yielded 
a data sample of 205 participants, of which 73.7% 
was female (n = 151). The age range of patients at 
intake was 18 to 69 years, with a mean age of 
39.5 years (SD = 12.4). 
2.2. Procedure 
The study was performed in accordance with the 
precepts and regulations for research as stated in 
the Declaration of Helsinki and the Dutch Medical 
Research on Humans Act (World Medical 
Organisation, 2001) concerning scientific research. 
All data were collected using the standard assessment 
instruments and regular monitoring outcome proce-
dure for the PSYTREC mental health centre. In addi-
tion, the study lacked random allocation, and no 
additional physical infringement of the physical 
and/or psychological integrity of the individual was 
to be expected (World Medical Association, 2001). 
During the two intake sessions, the inclusion cri-
teria were checked with the CAPS-5. If the patient 
met the inclusion criteria, the patient was invited to 
sign a treatment contract and informed consent for 
research purposes. Between the first and second 
intake, patients were asked to fill out the SIMS online 
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at home. Nine days after the last treatment day, 
patients returned to the treatment centre for the post- 
treatment assessment (CAPS-5) and were asked to fill 
out the SIMS online at home beforehand. 
2.3. Treatment programme 
After the intake procedure, patients started the 
intensive trauma-focused treatment programme for 
eight days. Patients received treatment for four days, 
after which they returned home for the weekend, 
and returned for another four consecutive days of 
treatment. During the treatment days, the patients 
stayed in the clinic, and each day they received 
individual Prolonged Exposure (PE) therapy in the 
morning, and individual Eye Movement and 
Desensitization Reprocessing (EMDR) therapy in 
the afternoon, both sessions lasting 90 minutes. 
During the rest of the day, the patients participated 
in physical activity and psycho-education. 
Therapists were trained clinical psychologists. Of 
note, therapists were unaware of the SIMS scores 
of their patients. For a more detailed description of 
the treatment programme, see Van Woudenberg 
et al. (2018). 
2.4. Measures 
2.4.1. Symptom overreporting 
Symptom overreporting was measured with the Dutch 
version of the Structured Inventory of Malingered 
Symptomatology (SIMS; Merckelbach, Koeyvoets, 
Cima, & Nijman, 2001; Widows & Smith, 2005), at pre- 
and post-treatment. The SIMS has 75 dichotomous 
items (range 0–75) that assess for exaggeration and 
overreporting. The SIMS has appropriate reliability 
and validity. Several cut-off scores have been suggested 
for the SIMS. To take into account that we measured 
symptom overreporting in a severe clinical population 
and symptom overreporting may be due to genuine 
symptoms, we used the rather high cut-off score of 24, 
as is recommended in previous studies (van Impelen, 
Merckelbach, Jelicic, & Merten, 2014; Wisdom, 
Callahan, & Shaw, 2010). The reliability of the SIMS 
in the present study was good (Cronbach’s alpha = .80 
(pre-treatment) and .86 (post-treatment)). 
2.4.2. PTSD symptom severity 
Treatment outcome was measured using the Dutch ver-
sion of the Clinician-Administered PTSD Scale (CAPS- 
5; Boeschoten et al., 2018) a structured clinical interview 
with adequate psychometric properties. Interviewers 
were not aware of the SIMS scores of the participants. 
2.4.3. Comorbid psychiatric disorders 
The Dutch version of the Mini-International 
Neuropsychiatric Interview (MINI; Overbeek, 
Schruers, & Griez, 1999) was used to assess comorbid 
psychiatric disorders and suicidal ideation at baseline. 
2.5. Statistical analyses 
IBM SPSS Statistics version 24 was used to perform 
the statistical analyses. An α level of .05 (two-sided) 
was adopted for all analyses. To test the main hypoth-
eses, a factorial mixed ANOVA was conducted with 
respectively the CAPS-5 and SIMS score over time 
(pre- and post-treatment) as the within-subjects fac-
tor and a positive screen on the SIMS (≥ 24 vs < 24) 
as the between-subjects factor. 
3. Results 
3.1. Sample characteristics 
Using a high SIMS cut-off of 24 or above, 14.1% 
(n = 29) had elevated SIMS scores, further indicated 
as ‘overreporters’. Patients reported multiple traumas, 
among those were sexual abuse (83.9%), physical abuse 
(82.0%), natural disasters, accidents and war (22.0%) 
and work-related traumas (8.8%). A high comorbidity 
rate was measured, as 95.1% of the sample had one or 
more comorbidities, and 30.2% had high suicidal risk. 
SIMS and CAPS-5 total scores were significantly corre-
lated (r(205) = .30, p < .001). There were no significant 
differences between the two groups with regard to age, 
sex, trauma type, and comorbidity. 
3.2. Effect of overreporting on treatment 
outcome 
In Table 1 the mean CAPS-5 and SIMS total scores are 
depicted at pre- and post-treatment for each group. For 
the CAPS-5, the factorial mixed ANOVA showed 
a significant main effect of time, F(1, 203) = 233.50, 
p < .001, ηp2 = 0.54 (large effect), and group, F(1, 
203) = 7.36, p = .007, ηp2 = 0.04 (small effect). This 
indicates that both groups showed large declines in 
PTSD symptoms over time, and that the overreporters 
scored significantly higher on PTSD symptoms at pre- 
and post-treatment than their non-malingering coun-
terparts. No significant interaction-effect was found, F 
(1, 203) = 0.21, p = .65, indicating that both groups 
profited equally from treatment (see Figure 1). 
3.3. Effect of treatment on SIMS scores 
At post-treatment, SIMS data of 21 participants were 
missing, and these participants were excluded from 
analysis. The factorial mixed ANOVA showed 
a significant main effect of time, F(1, 182) = 86.60, 
p < .001, ηp2 = 0.32 (large effect), and group, F(1, 
182) = 112.10, p < .001, ηp2 = 0.38 (large effect). This 
indicates that both groups showed large declines in 
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SIMS symptoms over time, and that overreporters 
scored significantly higher on SIMS symptoms at pre- 
and post-treatment. A significant interaction-effect was 
found, F(1, 182) = 35.82, p < .001, ηp2 = 0.16 (medium 
effect), indicating that the overreporters showed 
a stronger decrease in SIMS scores than the non- 
overreporters. At post-treatment, 19 patients (65.5%) 
did not reach the SIMS cut-off score of 24 anymore 
(mean 12.56, SD = 6.83, range 4–23), while 10 patients 
(35.5%) still scored above the cut-off score (mean 31.20, 
SD = 7.27, range 24–45). Although the latter group 
showed large effects of PTSD treatment results (CAPS 
Cohen’s d = 1.12), they showed significantly less 
decrease in CAPS-scores from pre- to post-treatment 
than the former group (t (27) = 2.36, p < .05). In the 
group of overreporters, the correlation between 
a decrease in CAPS-5 scores and SIMS scores was 
high (r(26) = .70, p < .001). In the total group this 
correlation was somewhat lower (r(184) = .47, p < .001). 
4. Discussion 
We found that in a treatment-seeking population, 
a part of the PTSD patients (14.1%) overreported 
their symptoms. Although it is often suggested that 
PTSD-patients who overreport should be excluded 
from treatment, we found that within the context of 
an intensive trauma-focused treatment programme, 
patients who overreported their symptoms showed 
good treatment results with large effect sizes. What 
is more, these treatment results did not differ signifi-
cantly from other patients. Also, we found that in the 
group of overreporters, symptom overreporting 
scores declined significantly from pre- to post- 
treatment. 
Some participants (5% of the total sample, 35% of the 
symptom overreporters), however, continued to overre-
port their symptoms at post-treatment, and these patients 
may have been malingerers. This percentage of malinger-
ing is in line with the literature (15% ± 15%, e.g. Young, 
2015), and because we used a high SIMS cut-off score for 
overreporting, leaving no room for false positives (van 
Impelen et al., 2014), these patients are suspected of 
malingering. However, because we did not collect objec-
tive information about their trauma exposures and exter-
nal incentives, we cannot draw this conclusion with 
certainty. Interestingly, although the treatment effects 
were lower than those of patients who did not continue 
to overreport their symptoms at post-treatment, these 
presumed malingerers also showed large treatment 
effects. 
Patients who malinger are assumed to have external 
motives for pretending to have the diagnosis PTSD, and 
therefore it is not likely that they would respond to 
treatment. Several explanations might account for the 
present findings. As mentioned in the introduction, 
symptom overreporting is likely to have other underlying 
reasons than malingering (see for a review Merckelbach 
et al., 2018). Our findings showed that symptom over-
reporting was significantly related with PTSD-symptom 
severity at baseline and that the decrease of symptom 
overreporting was significantly and highly related to 
a decrease of PTSD-symptoms. Therefore, it is likely 
that symptom overreporting may be caused by overlap-
ping PTSD symptoms, or to inattentive responding due 
to genuine PTSD-symptoms (or co-morbid symptoms), 
Table 1. Mean (SD) scores on CAPS-5 and SIMS on pre- and post-treatment.   
Overreporters Non-overreporters 
CAPS-5 N 29 176  
Pre-treatment 47.90 (8.10) 42.78 (8.53)  
Post-treatment 25.62 (20.43) 19.13 (15.64) 
SIMS N 26 158  
Pre-treatment 30.19 (5.54), range 24–42 13.54 (4.98), range 2–23  
Post-treatment 19.73 (11.51), range 4–45 11.27 (6.77), range 1–19 
SIMS = Structured Inventory of Malingered Symptomatology, CAPS-5 = Clinician-Administered PTSD scale for DSM-5.  
Figure 1. Change in mean CAPS-5 score over the course of treatment for the overreporters (n = 29) and non-overreporters 
(n = 176). 
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such as concentration problems, dissociation and depres-
sion. This is in line with general findings from different 
controlled PTSD-treatment outcome studies, showing 
that symptoms overlapping with or related to PTSD 
decline along with the decrease in PTSD-symptoms (see 
for a review van Minnen, Zoellner, Harned, & Mills, 
2015). 
The main limitation of our study was that it lacked 
a control group and randomized design. Therefore, it 
remains unknown to what extent the change in symptom 
overreporting can be attributed to our treatment. 
Decrease in symptom overreporting may also have been 
caused by regression to the mean or other confounding 
factors (e.g. Hawthorne effect, see McCarney et al., 2007). 
In addition, we used the SIMS as a standalone screening 
measure for overreporting, and did not include objective 
measures for external motives of patients. Future research 
should use additive performance validity tests which 
measure cognitive underperformance (Merkelbach 
et al., 2019), and gather information about patients’ exter-
nal incentives. Further, our results are limited to PTSD 
patients in this specific clinical context, and cannot be 
generalized to other treatment settings, such as a forensic 
or military setting. 
The strengths are that we included a relatively 
large sample size consisting of a broad range of 
different trauma histories. This enhances the gen-
eralization of the results as these offer a broad 
representation of the clinical population diagnosed 
with severe forms of PTSD. Another strength is 
that the treatment period was very brief. This 
makes it unlikely that, due to revictimization or 
other experiences during the treatment period, the 
underlying (external) motives for overreporting 
would change. 
In conclusion, the present results not only suggest that 
trauma-focused treatment is effective for patients with 
severe forms of PTSD, regardless of positive scores for 
symptom overreporting, but also that symptom overre-
porting scores can decline during the course of treatment. 
Further, our findings show that overreporting of SIMS- 
symptoms alone is not per se indicative of intentional 
biased responding (e.g. malingering). Clearly, more 
research about the influence of overreporting on the 
treatment outcome of patients with PTSD in clinical 
settings is needed, including a multimodal approach 
that contains more valid and reliable detection measure-
ments for assessing symptom overreporting so that like-
lihood of misdiagnoses can be reduced. All in all, based 
on the present findings excluding patients who are over-
reporting their symptoms from trauma-focused treat-
ment is unjustified. 
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